Login to Your Account



Galaxy Hooks Roche for Preclinical Oncology Program

By Marie Powers
Staff Writer

Wednesday, September 26, 2012

Galaxy Biotech LLC jumped back into the big fish pond, inking exclusive worldwide development and commercialization rights to a humanized monoclonal antibody (mAb) targeting fibroblast growth factor 2 (FGF2) in cancer to Roche AG.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription